Stock Movers: Soc Gen, Hermes, AstraZeneca (Podcast)

French banking stocks, led by Societe Generale, declined following Prime Minister Lecornu's resignation, which sparked concerns over political instability in France and also impacted domestically exposed firms like Hermes. Conversely, AstraZeneca shares rose after its drug Datroway, co-developed with Daiichi Sankyo, demonstrated improved survival rates for breast cancer patients with a particularly hard-to-treat form of the disease.

Analysis

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Stock Movers • Browse all episodes Stock Movers: Soc Gen, Hermes, AstraZeneca Stock Movers Soc Gen, Hermes, AstraZeneca On this episode of Stock Movers: - Societe Generale fell as banks in France led the decline following news that Prime Minister Sebastien Lecornu resigned, sparking worries about further political turmoil in the country. - Hermes was one of the many Paris-listed small- and mid-caps, which are most exposed to the domestic economy, that also dropped following the headlines. - AstraZeneca shares rose after its drug with Daiichi Sankyo, Datroway, helped breast cancer patients with a particularly hard to treat form of the disease live longer. Oct 06, 2025 The European equity market is exhibiting significant divergence driven by conflicting macro and company-specific catalysts. In France, political turmoil following the resignation of Prime Minister Sebastien Lecornu has triggered a notable sell-off in domestically-focused assets. This is evidenced by the decline in French banking stocks, led by Societe Generale (GLE), and a broader drop among Paris-listed small- and mid-caps like Hermes, which are highly exposed to the domestic economy. The negative per-ticker sentiment for GLE at -0.7 reflects investor anxiety over this political instability. In stark contrast, AstraZeneca (AZN) shares have rallied, supported by a strongly positive sentiment score of 0.8. This upward movement is a direct result of a positive fundamental development: its co-developed drug, Datroway, demonstrated a survival benefit in a difficult-to-treat form of breast cancer. The overall mixed market sentiment score of 0.0 accurately captures this bifurcation between politically-driven regional weakness and fundamentally-driven strength in the pharmaceutical sector.

Key Decisions for Investors

• Investors with exposure to French equities, particularly banks like Societe Generale, should brace for further volatility and closely monitor political developments, as sustained instability could lead to further downside.
• The positive clinical data for AstraZeneca's Datroway materially de-risks a key asset in its oncology pipeline, presenting a compelling, fundamentally-driven catalyst that may support a long position or an increase in exposure.
• The current market environment underscores the value of a barbell strategy, balancing positions in fundamentally strong companies like AstraZeneca against hedges or reduced exposure to assets vulnerable to specific geopolitical risks, such as the current situation in France.